1. Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

3. Goals

4. Diagnosed Diabetes,

5. Despite Increasing Prevalence, T2D Remains Undertreated

6. Limitations of Conventional Glucose-Lowering Agents

7. Limitations of Conventional Glucose-Lowering Agents (cont)

8. The Need for Novel Antihyperglycemic Agents

9. Pathophysiologic Pathways Affecting Glycemic Control in T2D

10. SGLT2 and Glucose Control

11. SGLT2: Novel Target for Glucose Control

12. Currently FDA-approved SGLT2 Inhibitors

13. Glycosuria: Concerns in Urgent Care Settings

14. Clinical Trial Findings for SGLT2 Inhibitors

15. Clinical Trial Findings for SGLT2 Inhibitors: Extraglycemic Effects

18. SGLT2 Inhibitors: Risk of Hypotension

20. Treating Patients With Type 2 Diabetes and CKD

23. Abbreviations

24. Abbreviations (cont)

25. References

26. References (cont)

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)